May 6 (Reuters) - Galmed Pharmaceuticals Ltd GLMD.O:
GALMED ANNOUNCES FIRST TIME RESULTS IN ONCOLOGY STUDIES: ARAMCHOL SIGNIFICANTLY ENHANCES BAYER'S REGORAFENIB EFFECT IN GI CANCER MODELS
GALMED PHARMACEUTICALS LTD - ARAMCHOL AND REGORAFENIB COMBINATION REDUCES TUMOR GROWTH IN MICE
GALMED PHARMACEUTICALS LTD - PHASE 1B STUDY OF ARAMCHOL AND REGORAFENIB TO START Q4 2025
Source text: ID:nPn4b7Hxka
Further company coverage: GLMD.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.